Top-Rated StocksTop-RatedNASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis $47.79 -0.30 (-0.62%) Closing price 04:00 PM EasternExtended Trading$48.65 +0.86 (+1.80%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Guardant Health Stock (NASDAQ:GH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Guardant Health alerts:Sign Up Key Stats Today's Range$47.30▼$48.9950-Day Range$37.05▼$52.0452-Week Range$20.14▼$53.42Volume1.51 million shsAverage Volume2.28 million shsMarket Capitalization$5.92 billionP/E RatioN/ADividend YieldN/APrice Target$53.76Consensus RatingBuy Company Overview Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California. Read More Guardant Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreGH MarketRank™: Guardant Health scored higher than 90% of companies evaluated by MarketBeat, and ranked 94th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating score is 3.05, and is based on 21 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($2.90) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -14.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -14.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Guardant Health's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.05% of the float of Guardant Health has been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Guardant Health has recently decreased by 6.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-0.61 Percentage of Shares Shorted8.05% of the float of Guardant Health has been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Guardant Health has recently decreased by 6.40%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment1.01 News SentimentGuardant Health has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Guardant Health this week, compared to 9 articles on an average week.Search Interest13 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.MarketBeat Follows5 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,080,589.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Stock News HeadlinesAmirali Talasaz Sells 100,000 Shares of Guardant Health, Inc. (NASDAQ:GH) StockJuly 3, 2025 | insidertrades.comInsider Selling: Guardant Health, Inc. (NASDAQ:GH) Director Sells 3,213 Shares of StockJune 21, 2025 | insidertrades.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 16 at 2:00 AM | Crypto 101 Media (Ad)Guardant Health, Inc. (NASDAQ:GH) Director Myrtle S. Potter Sells 2,626 SharesJune 17, 2025 | insidertrades.comEvercore ISI Keeps Their Buy Rating on Guardant Health (GH)July 16 at 5:33 AM | theglobeandmail.comFirst Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection TestJuly 15 at 11:39 AM | businesswire.comGuardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025July 14 at 8:00 AM | businesswire.comGuardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To KnowJuly 11, 2025 | msn.comSee More Headlines GH Stock Analysis - Frequently Asked Questions How have GH shares performed this year? Guardant Health's stock was trading at $30.55 at the beginning of the year. Since then, GH stock has increased by 57.6% and is now trading at $48.1390. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Wednesday, April, 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The business's revenue for the quarter was up 20.8% on a year-over-year basis. Read the conference call transcript. When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's top institutional investors include Exchange Traded Concepts LLC (0.01%), MRA Advisory Group (0.01%), Fiduciary Alliance LLC (0.01%) and Fifth Third Bancorp (0.01%). Insiders that own company stock include Helmy Eltoukhy, Amirali Talasaz, Amelia Merrill, Myrtle S Potter, Kumud Kalia, Meghan V Joyce, Ian T Clark and Musa Tariq. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Salesforce (CRM), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings4/30/2025Today7/16/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:GH CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees2,021Year FoundedN/APrice Target and Rating Average Price Target for Guardant Health$53.76 High Price Target$70.00 Low Price Target$35.00 Potential Upside/Downside+12.6%Consensus RatingBuy Rating Score (0-4)3.05 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$436.37 million Net Margins-53.82% Pretax Margin-53.67% Return on EquityN/A Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio3.76 Sales & Book Value Annual Sales$739.02 million Price / Sales8.01 Cash FlowN/A Price / Cash FlowN/A Book Value($1.13) per share Price / Book-42.27Miscellaneous Outstanding Shares123,890,000Free Float116,331,000Market Cap$5.92 billion OptionableNot Optionable Beta1.44 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:GH) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardant Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.